Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) View Full Press Release Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the First and Only Approved Medicine for FSGS